Selected Literature

Switching residues: A platform for the synthesis of Fidaxomin antibiotics.
Jung E, Griesser T, Costafrolaz J, Duverger O, Mattenberger Y, Dittmann S, Dorst A, Major A, Dailler D, Schäfle D, Sievers S, Brodolin K, Viollier PH, Sander P, Gademann K (2024)
Angewandte Chemie Int Ed: in press

Durlobactam boosts the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease.
Negatu DA, Aragaw W, Gebresilase TT, Shin SJ, Sander P, Dartois V, Dick T, Paruchuri S, Kaya F (2024)
Antimicrob Agents Chemother: in press

Synthesis and antibacterial action of 3',6'-disubstituted spectinomycins.
Dharuman S, Phelps GA, Dunn CM, Wilt LA, Murphy PA, Lee RB, Snoke HE, Selchow P, Haldimann K, Böttger EC, Hobbie SN, Sander P, Lee RE (2024)
J Antibiot (Tokyo) 77: 577-588

Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus.
Phelps GA, Cheramie MN, Fernando DM, Selchow P, Meyer CJ, Waidyarachchi SL, Dharuman S, Liu J, Meuli M, Molin MD, Killam BY, Murphy PA, Reeve SM, Wilt LA, Anderson SM, Yang L, Lee RB, Temrikar ZH, Lukka PB, Meibohm B, Polikanov YS, Hobbie SN, Böttger EC, Sander P, Lee RE (2024)
Proc Natl Acad Sci 121: e2314101120

Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species.
Jung E, Kraimps A, Dittmann S, Griesser T, Costafrolaz J, Mattenberger Y, Jurt S, Viollier PH, Sander P, Sievers S, Gademann K (2023)
Chembiochem 24: e202300570

Longitudinal increase in the detection rate of Mycobacterium chimaera in heater-cooler device-derived water samples.
Schreiber PW, Zihlmann R, Schärer V, Hasse B, Imkamp F, Schulthess B, Sander P, Zingg W (2023)
J Hosp Infect 131: 190-193

The aminoglycoside modifying enzyme Eis2 represents a new potential in vivo target for reducing antimicrobial drug resistance in Mycobacterium abscessus complex.
Lorè NI, Saliu F, Spitaleri A, Schäfle D, Nicola F, Cirillo DM, Sander P (2022)
Eur Respir J 60: 2201541

The aminoglycoside modifying enzyme Eis2 represents a new potential in vivo target for reducing antimicrobial drug resistance in Mycobacterium abscessus complex.
Lorè NI, Saliu F, Spitaleri A, Schäfle D, Nicola F, Cirillo DM, Sander P (2022)
Eur Respir J 60: 2201541

Apramycin overcomes the inherent lack of antimicrobial bactericidal activity in Mycobacterium abscessus.Selchow P, Ordway DJ, Verma D, Whittel N, Petrig A, Hobbie SN, Böttger EC, Sander P (2022)
Antimicrob Agents Chemother 66: e0151021

Aquimarins, peptide antibiotics with amino-modified C-termini from a sponge-derived Aquimarina sp. bacterium.
Dieterich CL, Probst SI, Ueoka R, Sandu I, Schäfle D, Dal Molin M, Minas HA, Costa R, Oxenius A, Sander P, Piel J (2022)
Angew Chem Int Ed Engl 61: e202115802

Photochemically-mediated inflammation and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4 and CD8 T-cell responses in mice.
Waeckerle-Men Y, Kotkowska ZK, Bono G, Duda A, Kolm I, Varypataki EM, Amstutz B, Meuli M, Høgset A, Kündig TM, Halin C, Sander P, Johansen P (2022)
Front Immunol 13: 815609

Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous mycobacteria.
Schulthess B, Schäfle D, Kälin N, Widmer T, Sander P (2021)
Antimicrob Agents Chemother 65: e02131-20

Rifabutin is inactivated by Mycobacterium abscessus Arr.
Schäfle D, Selchow P, Borer B, Meuli M, Rominski A, Schulthess B, Sander P (2021)
Antimicrob Agents Chemother 65: e02215-20

Novel fidaxomicin antibiotics through site-selective catalysis.
Dailler D, Dorst A, Schäfle D, Sander P, Gademann K (2021)
Commun Chem 4: 59

Mycobacterium tuberculosis phosphoribosyltransferase promotes bacterial survival in macrophages by inducing histone hypermethylation in autophagy-regulated genes.
Sengupta S, Nayak B, Meuli M, Sander P, Mishra S, Sonawane A (2021)
Front Cell Infect Microbiol 11: 676456

Mortality from drug-resistant tuberculosis in high-burden countries comparing routine drug susceptibility testing with whole-genome sequencing: a multicentre cohort study.
Züricher K, Reichmuth ML, Ballif M, Loiseau C, Borrell S, Reinhard M, Skrivankova V, Hömke R, Sander P, Avihingsanon A, Abimiku AG, Marcy O, Collantes J, Carter EJ, Wilkinson RJ, Cox H, Yotebieng M, Huebner R, Fenner L, Böttger EC, Gagneux S, Egger M, on behalf of IeDEA (2021)
Lancet Microbe 2: e320-330

Semisynthetic analogs of the antibiotic fidaxomicin-design, synthesis, and biological evaluation.
Dorst A, Berg R, Gertzen CGW, Schäfle D, Zerbe K, Gwerder M, Schnell SD, Sander P, Gohlke H, Gademann K (2020)
ACS Med Chem Let 11: 2414-2420

Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics
Dorst A, Shchelik IS, Schäfle D, Sander P, Gademann K (2020)
Helv Chim Acta 103: e2000130

KatG as counterselection marker for nontuberculous mycobacteria.
Gagliardi A, Selchow P, Luthra S, Schäfle D, Schulthess B, Sander P (2020)
Antimicrob Agents Chemother 64: e02508-19  

Natural polymorphisms in Mycobacterium tuberculosis conferring resistance to delamanid in drug-naïve patients.
Reichmuth ML, Hömke R, Zürcher K, Sander P, Avihingsanon A, Collantes J, Loiseau C, Borrell S, Reinhard M, Wilkinson RJ, Yotebieng M, Fenner L, Böttger EC, Gagneux S, Egger M, Keller PM (2020)
Antimicrob Agents Chemother 64: e00513-20

Diversity of nontuberculous mycobacteria in Heater-Cooler Devices - results from prospective surveillance.
Kaelin MB, Kuster SP, Hasse B, Schulthess B, Imkamp F, Halbe M, Sander P, Sax H, Schreiber PW (2020)
J Hosp Infect 105: 480-485

Identification of novel scaffolds targeting Mycobacterium tuberculosis.
Dal Molin M, Selchow P, Schäfle D, Tschumi A, Ryckmans T, Laage-Witt S, Sander P (2019)
J Mol Med 97: 1601-1613

BATF3-dependent dendritic cells drive both effector and regulatory T-cell responses in bacterially infected tissues.
Arnold IC, Zhang X, Artola-Boran M, Fallegger A, Sander P, Johansen P, Müller A (2019)
PLoS Pathog 15: e1007866

Increased drug permeability of a stiffened mycobacterial outer membrane in cells lacking MFS transporter Rv1410 and lipoprotein LprG.
Hohl M, Remm S, Eskandarian HA, Dal Molin M, Arnold FM, Hürlimann LM, Krügel A, Fantner GE, Sander P, Seeger MA (2019)
Mol Microbiol 111: 1263-1282

Whole genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis
Gygli S, Keller P, Ballif M, Blöchliger N, Hömke R, Reinhard M, Loiseau C, Ritter C, Sander P, Borrell S, Collantes J, Avihingsanon A, Gnokoro J, Yotebieng M, Egger M, Gagneux S, Böttger EC (2019)
Antimicrob Agents Chemother 63: e02175-18

International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass.
Hasse B, Hannan M, Keller PM, Maurer FP, Sommerstein R, Mertz D, Wagner D, Fernández-Hidalgo N, Nomura J, Manfrin V, Bettex D, Conte AH, Durante-Mangoni E, Hing-Cheung Tang T, Stuart RL, Lundgren J, Gordon S, Jarashow MC, Schreiber PW, Niemann S, Kohl TA, Daley C, Stewardson AJ, Whitener CJ, Perkins K, Plachouras D, Lamagni T, Chand M, Freiberger T, Zweifel S, Sander P, Schulthess B, Scriven J, Sax H, van Ingen J, Mestres CA, Diekema D, Brown-Elliott BA, Wallace RJ Jr, Baddour LM, Miro JM, Hoen B; M. chimaera ISCVID investigators; Infectious Diseases specialists; Hospital epidemiologists; Microbiologists and molecular typing specialists; Cardiac surgeons/ perfusionists/ cardiologists; Ophthalmology; Anaesthesiologists; Public Health (2020)
J Hosp Infect 104: 214-235

The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance.
Luthra S, Rominski A, Sander P (2018)
Front Microbiol 9: 2179

Molecular mechanisms of intrinsic streptomycin resistance in Mycobacterium abscessus.
Dal Molin M, Gut M, Rominski A, Haldimann K, Becker K, Sander P (2018)
Antimicrob Agents Chemother 62

Lipoprotein glycosylation by protein-O-mannosyltransferase (MAB_1122c) contributes to low cell envelope permeability and antibiotic resistance in Mycobacterium abscessus.
Becker K, Haldimann K, Selchow P, Reinau LM, Dal Molin M, Sander P (2017)
Frontiers Microbiology 8: 2123

Effect of β-lactamase production and β-lactam instability on MIC testing results of Mycobacterium abscessus.
Rominski A, Schultess B, Müller D, Keller P, Sander P (2017)
J Antimicrob Chemother 72: 3070-3078

Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes.
Rominski A, Selchow P, Becker K, Brülle JK, Dal Molin M, Sander P (2017)
J Antimicrob Chemother 72: 2191-2200

Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux.
Matt U, Selchow P, Dal Molin M, Strommer S., Sharif O, Schilcher K, Andreoni F, Stenzinger A, Zinkernagel AS, Zeitlinger M, Sander P, Nemeth J (2017)
Int J Antimicrob Agents 50: 55-62

Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.
Rominski A, Roditscheff A, Selchow P, Böttger EC, Sander P (2017)
J Antimicrob Chemother 72: 376-384

TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development.
Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A; TBVAC2020 Consortium (2017)
Front Immunol 8: 1203

Lipase Processing of Complex Lipid Antigens.
Sander P, Becker K, Molin MD (2016)
Cell Chem Biol 23: 1044-1046

M. tuberculosis lipoproteins in virulence and immunity: fighting with a double-edged sword.
Becker K, Sander P (2016)
FEBS Lett: 590: 3800-3819

Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis.
Sander P, Clark S, Petrera A, Vilaplana C, Meuli M, Selchow P, Zelmer A, Mohanan D, Andreu N, Rayner E, Dal Molin M, Bancroft GJ, Johansen P, Cardona PJ, Williams A, Böttger EC (2015)
Vaccine 33: 1353-1359

Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire.
Lepore M, Kalinicenko A, Colone A, Paleja B, Singhal A, Tschumi A, Lee B, Poidinger M, Zolezzi F, Quagliata L, Sander P, Newell E, Bertoletti A, Terracciano L, De Libero G, Mori L (2014)
Nat Commun 5: 3866

Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor.
Mori M, Moraca F, Deodato D, Ferraris DM, Selchow P, Sander P, Rizzi M, Botta M (2014)
Bioorg Med Chem Lett 24: 2508-2511

BCG Δzmp1 vaccine induces enhanced antigen specific immune responses in cattle.
Khatri B, Whelan A, Clifford D, Petrera A, Sander P, Vordermeier HM (2014)
Vaccine 32: 779-784

Lipoproteins of slow-growing Mycobacteria carry three fatty acids and are N-acylated by apolipoprotein N-acyltransferase BCG_2070c.
Brülle JK, Tschumi A, Sander P (2013)
BMC Microbiol 13: 223

Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis.
Waeckerle-Men Y, Bruffaerts N, Liang Y, Jurion F, Sander P, Kündig TM, Huygen K, Johansen P (2013)
Vaccine 31: 1057-1064

Functional analyses of mycobacterial lipoprotein diacylglyceryl transferase and comparative secretome analysis of a mycobacterial lgt mutant.
Tschumi A, Grau T, Albrecht D, Rezwan M, Antelmann H, Sander P (2012)
J Bacteriol 194: 3938-3949

Functional characterization of the Mycobacterium tuberculosis zinc metallopeptidase Zmp1 and identification of potential substrates.
Petrera A, Amstutz B, Gioia M, Hähnlein J, Baici A, Selchow P, Ferraris DM, Rizzi M, Sbardella D, Marini S, Coletta M, Sander P (2012)
Biol Chem 393: 631-640

Phenylethyl-butyrate enhances the potency of second-line drugs against clinical isolates of M. tuberculosis.
Grau T, Selchow P, Tigges M, Burri R, Gitzinger M, Böttger EC, Fussenegger M, Sander P (2012)
Antimicrob Agents Chemother 56: 1142-1145

Crystal structure of Mycobacterium tuberculosis ZMP1, a metalloprotease involved in pathogenicity.
Ferraris DM, Sbadrdella D, Petrera A, Marini S, Amstutz B, Coletta M, Sander P, Rizzi M (2011)
J Biol Chem 286: 32475-32482

Relief from zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.
Johansen P, Fettelschoss A, Amstutz B, Selchow P, Wäckerle-Men Y, Keller P, Deretic V, Held L, Kündig TM, Böttger EC, Sander P (2011)
Clin Vaccine Immunol 18: 907-913

Dissecting the complete lipoprotein biogenesis pathway in Streptomyces scabies.
Widdick DA, Hicks MG, Thompson BJ Tschumi A, Chandra G, Sutcliffe IC, Brülle JK, Sander P, Palmer T, Hutchings MI (2011)
Mol Microbiol 80: 1395-1412

Deletion of dop in Mycobacterium smegmatis abolishes pupylation of protein substrates in vivo.
Imkamp F, Rosenberger T, Striebel F, Keller PM, Amstutz B, Sander P, Weber-Ban E (2010)
Mol Microbiol 75: 744-754

Cloning, expression and characterization of Mycobacterium tuberculosis lipoprotein LprF.
Brülle JK, Grau T, Tschumi A, Auchli Y, Burri R, Polsfuss S, Keller PM, Hunziker P, Sander P (2010)
Biochem Biophys Res Commun 391: 679-684

Dop functions as a depupylase in the prokaryotic ubiquitin-like modification pathway.
Imkamp F, Striebel F, Sutter M, Özcelik D, Sander P, Weber-Ban E (2010)
EMBO Reports 11: 791-797

Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting.
Joller N, Weber SS, Müller AJ, Spörri R, Selchow P, Sander P, Hilbi H, Oxenius A (2010)
Proc Natl Acad Sci USA 107: 20441-20446

Identification of apolipoprotein n-acyltransferase (LNT) in mycobacteria.
Tschumi A, Nai C, Auchli Y, Hunziker P, Gehrig P, Keller P, Grau T, Sander P (2009)
J Biol Chem 284: 27146-27156

Involvement of CD252 (CD134L) and IL-2 in the expression of cytotoxic proteins in bacterial- or viral-activated human T cells.
Walch M, Rampini SK, Stöckli I, Latinovic-Golic S, Dumrese C, Sundstrom H, Vogetseder A, Marino J, Glauser DL, van den Broek M, Sander P, Groscurth P, Ziegler U (2009)
J Immunol 182: 7569-7579

Polyphosphates from Mycobacterium bovis - potent inhibitors of class III adenylate cyclases.
Guo YL, Mayer H, Vollmer W, Dittrich D, Sander P, Schultz A, Schultz JE (2009)
FEBS J 276: 1094-1103

LspA-inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest.
Rampini SK, Selchow P, Keller C, Ehlers S, Böttger EC, Sander P (2008)
Microbiology 154:  2991-3001

A synthetic mammalian gene circuit reveals anti-tuberculosis compounds.
Weber W, Schoenmakers R, Keller B, Grau T, Gitzinger M, Daoud-El Baba M, Sander P, Fussenegger M (2008)
Proc Natl Acad Sci USA 105: 9994-9998

Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant.
Keller P, Böttger EC, Sander P (2008)
BMC Microbiol 8: 120

Mycobacterium tuberculosis prevents inflammasome activation.
Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, Springer B, Timmins GS, Sander P, Deretic V (2008)
Cell Host Microbe 3: 224-232